# Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

> **NCT05904691** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Ocugenix Corporation** · enrollment: 24 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration (nAMD)

## Interventions

- **DRUG:** OCU-10-C-110 for Injection

## Key facts

- **NCT ID:** NCT05904691
- **Lead sponsor:** Ocugenix Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904691, "Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05904691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*